Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: Evidence derived from the study of peripheral arterial disease

Circulation

Volumn 96, Issue 1, 1997, Pages 69-75

  Davì, Giovanni ^b   Gresele, Paolo ^b   Violi, Francesco ^b   Basili, Stefania ^b   Catalano, Mariella ^b   Giammarresi, Carlo ^b   Volpato, Raul ^b   Nenci, Giuseppe G ^b   Ciabattoni, Giovanni ^b   Patrono, Carlo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b NONE

Author keywords

Diabetes mellitus; Hypercholesterolemia; Hypertension; Peripheral vascular disease; Thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINORTHROMBOXANE B2; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT; THROMBOXANE; THROMBOXANE A2; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BIOSYNTHESIS; BLOOD PRESSURE; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ACTIVATION; URINARY EXCRETION;

EID: 0030754003     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.1.69     Document Type: Article

References (50)

1. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and arterial function in healthy individuals who smoke cigarettes. Circulation. 1987; 76:6-14.
2. Barrow SE, Ward PS, Sleightholm MA, Ritter JM, Dollery CT. Cigarette smoking: profiles of thromboxane- and prostacyclin-derived products in human urine. Biochim Biophys Acta. 1989;993: 121-127.
3. Uedelhoven WM, Rutzel A, Meese CO, Weber PC. Smoking alters thromboxane metabolism in man. Biochim Biophys Acta. 1991;108: 197-201.
4. Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769-1774.
5. Davì G, Averna M, Catalane I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 1992;85:1792-1798.
6. Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C, Mancini M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria: evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400-1406.
7. Patrono C, Davì G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med. 1992;2:15-20.
8. Criqui MH, Coughlin SS, Fronek A. Noninvasive diagnosed peripheral arterial disease as a predictor of mortality: results from a prospective study. Circulation. 1985;4:768-773.
9. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326: 381-386.
10. Coffmann JD. Intermittent claudication: be conservative. N Engl J Med. 1991;325:577-578.
11. Criqui MH, Browner D, Fronek A, Klauber MR, Barrett-Connor E, Coughlin SS. Gabriel S. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease: an analysis of risk factors. Am J Epidemiol. 1989;129:1110-1119.
12. Violi F, Criqui M, Longoni A, Castiglioni C, and the ADEP Group. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease: results from the ADEP Study. Atherosclerosis. 1996;120:25-35.
13. 2 as an amplifying signal for other agonists. Am J Cardiol. 1991;68: 11B-15B.
14. Rose GA. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27: 117-126.
15. Fronek A. Noninvasive Diagnostics in Arterial Disease. New York, NY: McGraw-Hill; 1989:88-94.
16. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK, for the Cardioarterial Health Study (CHS) Collaborative Research Group. Ankle-arm index as a marker of atherosclerosis in the Cardioarterial Health Study. Circulation. 1993;88:837-845.
17. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 1991;87:119-128.
18. Dormandy JA, Murray GD. The fate of the claudicant: a prospective study of 1969 claudicants. Eur J Vasc Surg. 1991;5:131-133.
19. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
20. WHO memorandum. Classification of hyperlipidemias and hyperlipoproteinemias. Circulation. 1972;45:501-508.
21. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
22. 2 in man: identification of twenty urinary metabolites. J Biol Chem. 1981;256:8384-8393.
23. 2 in human plasma and urine. Biochim Biophys Acta. 1987;918:29-37.
24. 2 production in patients with systemic lupus erythematosus. J Clin Invest. 1985;76:1011-1018.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
26. Notarbartolo A, Davì G, Averna M, Barbagallo MB, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb. 1995;15: 247-251.
27. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York, NY: McGraw Hill; 1956:184.
28. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
29. 2 in man. Biochim Biophys Acta. 1989;992:66-70.
30. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983;67:1174-1177.
31. Ogren M, Hedblad B, Isacsson O, Janzon L, Jungquist G, Lindell SE. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet. 1993;342: 1138-1141.
32. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
33. Rangemark C, Ciabattoni G, Wennmalm A. Excretion of thromboxane metabolites in healthy women after cessation of smoking. Arterioscler Thromb. 1993;13:777-782.
34. Minuz P, Barrow SE, Cockroft JR, Ritter JM. Prostacyclin and thromboxane biosynthesis in mild essential hypertension. Hypertension. 1990;15:469-474.
35. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane metabolites in humans. Thromb Res. 1987;47:647-656.
36. Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 1990;63:163-168.
37. Knapp HR, Healy C, Lawson J, FitzGerald GA. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. Thromb Res. 1988;50:377-386.
38. 2 and prostacyclin synthesis by low dose acetylsalicylic acid in atherosclerotic patients. Thromb Res. 1990;57: 437-444.
39. Reilly IAG, Doran JB, Smith B, FitzGerald GA. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation. 1986;73:1300-1309.
40. Ejim OS, Powling MJ, Dandona P, Kernoff PBA, Goodall AH. A flow cytometric analysis of fibronectin binding to platelets from patients with peripheral arterial disease. Thromb Res. 1990;58: 519-524.
41. Devine DV, Anderstad G, Nugent D, Carter CJ. Platelet-associated factor XIII as a marker of platelet activation in patients with peripheral arterial disease. Arterioscler Thromb. 1993;13:857-862.
42. Sinzinger H, Virgolini I, Fitscha P. Platelet kinetics in patients with atherosclerosis. Thromb Res. 1990;57:507-516.
43. Cella G, Zahavi J, de Haas HA, Kakkar VV. β-Thromboglobulin, platelet production time and platelet function in arterial disease. Br J Haematol. 1979;43:127-136.
44. Baele G, Bogaerts H, Clements DL, Pannier R, Barbier F. Platelet activation during treadmill exercise in patients with chronic peripheral arterial disease. Thromb Res. 1981;23:215-223.
45. Verstraete M. Platelet activation in patients with atherosclerosis of the arteries of the limbs. In: Vanhoutte PM, ed. Serotonin and the Cardioarterial System. New York, NY: Raven Press; 1985:171-177.
46. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984;310:1065-1068.
47. Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood. 1981;57: 199-202.
48. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
49. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease: a double-blind placebo-controlled study - the ADEP Group. Circulation. 1993;87:1563-1569.
50. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330: 1287-1294.